2020
Estrogen Plus Progestin Hormone Therapy and Ovarian Cancer: A Complicated Relationship Explored.
Lee A, Wu A, Wiensch A, Mukherjee B, Terry K, Harris H, Carney M, Jensen A, Cramer D, Berchuck A, Doherty J, Modugno F, Goodman M, Alimujiang A, Rossing M, Cushing-Haugen K, Bandera E, Thompson P, Kjaer S, Hogdall E, Webb P, Huntsman D, Moysich K, Lurie G, Ness R, Stram D, Roman L, Pike M, Pearce C. Estrogen Plus Progestin Hormone Therapy and Ovarian Cancer: A Complicated Relationship Explored. Epidemiology 2020, 31: 402-408. PMID: 32028322, PMCID: PMC7584395, DOI: 10.1097/ede.0000000000001175.Peer-Reviewed Original ResearchConceptsRisk of ovarian cancerEstrogen-progestin combined therapyEstrogen-alone therapyAssociated with increased riskOvarian cancerCombination therapyRisk of ovarian cancer overallAssociated with increased risk of ovarian cancerOvarian cancer risk factorsPopulation-based case-control studyOvarian Cancer Association ConsortiumMenopausal hormone therapy useIncreased risk of endometrial cancerOvarian cancer overallRisk of endometrial cancerCancer risk factorsHistotypes of ovarian cancerRisk factorsProgestin hormone therapyMucinous ovarian cancerOvarian cancer casesIn-person interviewsHormone therapy useOvarian cancer histotypesCase-control study
2016
A splicing variant of TERT identified by GWAS interacts with menopausal estrogen therapy in risk of ovarian cancer
Lee A, Bomkamp A, Bandera E, Jensen A, Ramus S, Goodman M, Rossing M, Modugno F, Moysich K, Chang‐Claude J, Rudolph A, Gentry‐Maharaj A, Terry K, Gayther S, Cramer D, Doherty J, Schildkraut J, Kjaer S, Ness R, Menon U, Berchuck A, Mukherjee B, Roman L, Pharoah P, Chenevix‐Trench G, Olson S, Hogdall E, Wu A, Pike M, Stram D, Pearce C, Consortium F. A splicing variant of TERT identified by GWAS interacts with menopausal estrogen therapy in risk of ovarian cancer. International Journal Of Cancer 2016, 139: 2646-2654. PMID: 27420401, PMCID: PMC5500237, DOI: 10.1002/ijc.30274.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overAllelesAlternative SplicingCase-Control StudiesDisease SusceptibilityEstrogen Replacement TherapyFemaleGene-Environment InteractionGenome-Wide Association StudyGenotypeHumansMenopauseMiddle AgedOdds RatioOvarian NeoplasmsPolymorphism, Single NucleotidePopulation SurveillanceRiskTelomeraseConceptsOvarian Cancer Association ConsortiumEstrogen-alone therapyOvarian cancer riskEndometrioid ovarian cancerOvarian cancerET usersET useT alleleAssociated with ovarian cancer riskCancer riskLong-term ET usersOvarian cancer susceptibility lociRisk of ovarian cancerSusceptibility variantsMenopausal estrogen therapyCancer susceptibility lociSerous ovarian cancerSplice variantsNon-usersCase-control studyConditional logistic regressionGenome-wide association studiesIncreased risk of diseaseEndometrioid histotypeEstrogen therapy